Last month, the University of Pittsburgh Cancer Institute (UPCI) and Pitt’s School of Medicine and Graduate School of Public Health received a five-year, $18 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to continue work developing drugs that could provide protection from radiation in emergencies such as terrorism or reactor meltdowns.
Watch Joel S. Greenberger, MD, Claude Worthington Benedum Foundation Chair and Professor of Radiation Oncology, explain the collaborative research projects and cores supported by this award.
